98%
921
2 minutes
20
To evaluate the diagnostic value of plasma D-dimer combined with transvaginal ultrasonography for endometrial carcinoma in postmenopausal women, addressing the increasing incidence in China. This retrospective study analyzed 129 postmenopausal women (July 2021-January 2023) undergoing hysteroscopy, including 61 with endometrial carcinoma (mean age 56.5 ± 6.8 years) and 68 with benign lesions (60.2 ± 7.7 years). We assessed D-dimer levels, ultrasonographic parameters (endometrial thickness, uterine cavity occupation, blood flow signals), and postmenopausal bleeding. Diagnostic performance was evaluated using ROC curves. Multivariate analysis identified three independent predictors: intracavitary blood flow (OR 60.44, 95% CI 8.25-442.98, p < 0.001), postmenopausal bleeding (OR 5.84, 95% CI 1.82-18.75, p = 0.003), and elevated D-dimer (OR 3.12, 95% CI 1.06-9.22, p = 0.04). The comprehensive model achieved superior diagnostic performance (AUC = 0.920, sensitivity = 88.5%, specificity = 85.3%) compared to any individual parameter. Plasma D-dimer combined with transvaginal ultrasonography and clinical symptoms provides an effective screening approach for postmenopausal endometrial carcinoma, serving as a valuable risk assessment strategy for identifying candidates requiring definitive histopathological examination.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304256 | PMC |
http://dx.doi.org/10.1038/s41598-025-12980-x | DOI Listing |
Int J Clin Oncol
September 2025
Department of Obstetrics and Gynecology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
September 2025
Department of Biostatistics, Amrita Institute of Medical Sciences, Ponekkara Rd, Edappally, Kochi, Ernakulam 682041 Kerala, India.
Objective: This study compared the oncological outcomes of Pure Uterine Serous Carcinomas (p-USC) and p53-Abnormal Grade 3 Endometroid Endometrial Tumours (p53 Abn G3-EEC).
Methods: A retrospective study was conducted at Amrita Institute of Medical Sciences from February 1, 2015, to December 31, 2020, analysing patients diagnosed with P-USC and p53 Abn G3-EEC. The primary objective was to compare the 5-year Progression-Free Survival (PFS) between two groups.
Gynecol Oncol
September 2025
Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Objective: This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.
Methods: In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (POLE) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.
Results: We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.
Gynecol Oncol
September 2025
University of Chicago, Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Chicago, IL 60637, USA; University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL 60637, USA.
Objective: To identify associations between race, neighborhood disadvantage, and outcomes in women with stage I-III endometrioid endometrial cancer (EEC) treated at a tertiary referral center.
Methods: This retrospective tumor registry study included patients with stage I-III EEC between 1/2006 and 12/2022. Progression-free (PFS) and overall survival (OS) were analyzed by race and neighborhood disadvantage, stratified by Area Deprivation Index (ADI; national quartile).
J Robot Surg
September 2025
Department of Gynecology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Obesity is closely linked to an increased incidence of several gynecological conditions and poses significant challenges to their surgical management. Among these, endometrial cancer stands out due to its high prevalence in patients with elevated body mass index, with nearly 60% of those requiring primary surgical treatment classified as obese or morbidly obese. The coexistence of multiple comorbidities in this population contributes to a heightened risk of perioperative and postoperative complications.
View Article and Find Full Text PDF